Carmen Sulton1, Courtney McCracken1, Harold K Simon2, Kiran Hebbar3, Jason Reynolds4, Joseph Cravero5, Michael Mallory6, Pradip Kamat7. 1. Department of Pediatrics, and. 2. Department of Pediatrics, and Divisions of Pediatric Emergency Medicine and. 3. Department of Pediatrics, and Pediatric Critical Care Medicine, Emory University School of Medicine, Atlanta, Georgia; 4. Department of Pediatrics, Baylor College of Medicine, San Antonio, Texas; 5. Department of Anesthesiology, Boston Children's Hospital, Boston, Massachusetts; and. 6. Pediatric Emergency Medicine Associates, Children's Healthcare of Atlanta, Atlanta, Georgia. 7. Department of Pediatrics, and Pediatric Critical Care Medicine, Emory University School of Medicine, Atlanta, Georgia; pradip.kamat@choa.org.
Abstract
OBJECTIVES: Dexmedetomidine (DEX) is widely used in pediatric procedural sedation (PPS) by a variety of pediatric subspecialists. The objective of our study was to describe the overall rates of adverse events and serious adverse events (SAEs) when DEX is used by various pediatric subspecialists. METHODS: Patients from the Pediatric Sedation Research Consortium (PSRC) database were retrospectively reviewed and children that received DEX as their primary sedation agent for elective PPS were identified. Demographic and clinical data, provider subspecialty, and sedation-related complications were abstracted. SAEs were defined as death, cardiac arrest, upper airway obstruction, laryngospasm, emergent airway intervention, unplanned hospital admission/increased level of care, aspiration, or emergency anesthesia consult. Event rates and 95% confidence intervals (CIs) were calculated. RESULTS: During the study period, 13 072 children were sedated using DEX, accounting for 5.3% of all sedation cases entered into the PSRC. Of the sedated patients, 73% were American Society of Anesthesiologists Physical Status class 1 or 2. The pediatric providers responsible for patients sedated with DEX were anesthesiologists (35%), intensivists (34%), emergency medicine physicians (12.7%), hospitalists (1.1%), and others (17%). The overall AE rate was 466/13 072 (3.6%, 95% CI 3.3% to 3.9%). The overall SAE rate was 45/13 072 (0.34%, 95% CI 0.19% to 0.037%). Airway obstruction was the most common SAE: 35/13 072 (0.27%, 95% CI 0.19% to 0.37%). Sedations were successful in 99.7% of cases. CONCLUSIONS: We report the largest series of PPS using DEX outside the operating room. Within the PSRC, PPS performed using DEX has a very high success rate and is unlikely to yield a high rate of SAEs.
OBJECTIVES:Dexmedetomidine (DEX) is widely used in pediatric procedural sedation (PPS) by a variety of pediatric subspecialists. The objective of our study was to describe the overall rates of adverse events and serious adverse events (SAEs) when DEX is used by various pediatric subspecialists. METHODS:Patients from the Pediatric Sedation Research Consortium (PSRC) database were retrospectively reviewed and children that received DEX as their primary sedation agent for elective PPS were identified. Demographic and clinical data, provider subspecialty, and sedation-related complications were abstracted. SAEs were defined as death, cardiac arrest, upper airway obstruction, laryngospasm, emergent airway intervention, unplanned hospital admission/increased level of care, aspiration, or emergency anesthesia consult. Event rates and 95% confidence intervals (CIs) were calculated. RESULTS: During the study period, 13 072 children were sedated using DEX, accounting for 5.3% of all sedation cases entered into the PSRC. Of the sedated patients, 73% were American Society of Anesthesiologists Physical Status class 1 or 2. The pediatric providers responsible for patients sedated with DEX were anesthesiologists (35%), intensivists (34%), emergency medicine physicians (12.7%), hospitalists (1.1%), and others (17%). The overall AE rate was 466/13 072 (3.6%, 95% CI 3.3% to 3.9%). The overall SAE rate was 45/13 072 (0.34%, 95% CI 0.19% to 0.037%). Airway obstruction was the most common SAE: 35/13 072 (0.27%, 95% CI 0.19% to 0.37%). Sedations were successful in 99.7% of cases. CONCLUSIONS: We report the largest series of PPS using DEX outside the operating room. Within the PSRC, PPS performed using DEX has a very high success rate and is unlikely to yield a high rate of SAEs.
Authors: Bi Lian Li; Vivian Man-Ying Yuen; Na Zhang; Huan Huan Zhang; Jun Xiang Huang; Si Yuan Yang; Jeffery W Miller; Xing Rong Song Journal: J Autism Dev Disord Date: 2019-09
Authors: Jocelyn R Grunwell; Curtis Travers; Anne G Stormorken; Patricia D Scherrer; Corrie E Chumpitazi; Jana A Stockwell; Mark G Roback; Joseph Cravero; Pradip P Kamat Journal: Pediatr Crit Care Med Date: 2017-08 Impact factor: 3.624
Authors: Keira P Mason; Mark G Roback; David Chrisp; Nicole Sturzenbaum; Lee Freeman; David Gozal; Firoz Vellani; David Cavanaugh; Steven M Green Journal: J Clin Med Date: 2019-12-01 Impact factor: 4.241
Authors: Corrie E Chumpitazi; Cindy Chang; Zaza Atanelov; Ann M Dietrich; Samuel Hiu-Fung Lam; Emily Rose; Tim Ruttan; Sam Shahid; Michael J Stoner; Carmen Sulton; Mohsen Saidinejad Journal: J Am Coll Emerg Physicians Open Date: 2022-03-12
Authors: Camille E van Hoorn; Robert B Flint; Justin Skowno; Paul Davies; Thomas Engelhardt; Kirk Lalwani; Olutoyin Olutoye; Erwin Ista; Jurgen C de Graaff Journal: Eur J Clin Pharmacol Date: 2020-10-29 Impact factor: 2.953